(Reuters) -The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and Novo Nordisk, special vouchers that will speed up the review of their medicines, bringing the total number of recipients to 15. The vouchers went to treatments for cancer, obesity, tuberculosis and sickle cell disease.

() -​Rhythm Pharmaceuticals ‌said on Friday ‌the U. Food and ⁠Drug ‌Administration has extended the ‍review period for expanded approval ​of its ‌drug, Imcivree, as a treatment for ⁠a rare ​form ​of obesity.

The Trump administration on Thursday announced its newest pharmaceutical agreement under its Most Favored Nation (MFN) policy, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.

The dramatic shift in oversight comes at a time when the U.S. has never been more reliant on foreign food, which accounts for the vast majority of the nation’s seafood and more than half its fresh fruit.

The top drug regulator at the Food and Drug Administration (FDA) resigned Sunday, according to officials, after being accused of using his position of authority to publicly denigrate a treatment tied to a former business associate.

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one day before he was named in a federal defamation lawsuit filed in Maryland by Aurinia Pharmaceuticals Inc.

The FDA has sent warning letters to 18 websites selling counterfeit or unapproved versions of Botox and similar injectable drugs commonly used to smooth wrinkles.

New professional guidance to the nation's pediatricians advises against using a drug in children with autism that many families are clamoring for after it was hyped by federal officials.

Numerous recalls have been issued this year due to the potential for damaged products and undeclared food allergens.